Siegel Jolie has filed 17 insider transactions across 1 company since February 2024.
Most recent transaction: a tax payment of 2135 shares of C4 Therapeutics, Inc. ($CCCC) on February 13, 2025.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 13, 2025 | C4 Therapeutics, Inc. | $CCCC | Siegel Jolie | Chief Legal Officer | F | Common Stock | 2135 | $3.20 | 54,353.0000 | 0 | 3.78% | 0.00% |
| Feb. 14, 2025 | C4 Therapeutics, Inc. | $CCCC | Siegel Jolie | Chief Legal Officer | A | Common Stock | 56500 | $0.00 | 110,853.0000 | 0 | 103.95% | 0.00% |
| Feb. 14, 2025 | C4 Therapeutics, Inc. | $CCCC | Siegel Jolie | Chief Legal Officer | F | Common Stock | 2914 | $3.18 | 107,939.0000 | 0 | 2.63% | 0.00% |
| Feb. 14, 2025 | C4 Therapeutics, Inc. | $CCCC | Siegel Jolie | Chief Legal Officer | A | Stock Option (Right to Buy) | 84700 | $0.00 | 84,700.0000 | 0 | 9999.99% | 0.00% |
| Nov. 7, 2024 | C4 Therapeutics, Inc. | $CCCC | Siegel Jolie | Chief Legal Officer | M | Common Stock | 3750 | $0.00 | 57,590.0000 | 0 | 6.97% | 0.00% |
| Nov. 7, 2024 | C4 Therapeutics, Inc. | $CCCC | Siegel Jolie | Chief Legal Officer | F | Common Stock | 1102 | $6.04 | 56,488.0000 | 0 | 1.91% | 0.00% |
| Nov. 7, 2024 | C4 Therapeutics, Inc. | $CCCC | Siegel Jolie | Chief Legal Officer | M | Performance Restricted Stock Units | 3750 | $0.00 | 10,500.0000 | 0 | 26.32% | 0.00% |
| Sept. 16, 2024 | C4 Therapeutics, Inc. | $CCCC | Siegel Jolie | Chief Legal Officer | M | Common Stock | 2250 | $0.00 | 54,501.0000 | 0 | 4.31% | 0.00% |
| Sept. 16, 2024 | C4 Therapeutics, Inc. | $CCCC | Siegel Jolie | Chief Legal Officer | F | Common Stock | 661 | $6.36 | 53,840.0000 | 0 | 1.21% | 0.00% |
| Sept. 16, 2024 | C4 Therapeutics, Inc. | $CCCC | Siegel Jolie | Chief Legal Officer | M | Performance Restricted Stock Units | 2250 | $0.00 | 14,250.0000 | 0 | 13.64% | 0.00% |
| March 7, 2024 | C4 Therapeutics, Inc. | $CCCC | Siegel Jolie | Chief Legal Officer | D | Stock Option (Right to Buy) | 84850 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| March 7, 2024 | C4 Therapeutics, Inc. | $CCCC | Siegel Jolie | Chief Legal Officer | A | Stock Option (Right to Buy) | 84850 | $0.00 | 84,850.0000 | 0 | 9999.99% | 0.00% |
| March 7, 2024 | C4 Therapeutics, Inc. | $CCCC | Siegel Jolie | Chief Legal Officer | D | Stock Option (Right to Buy) | 90000 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| March 7, 2024 | C4 Therapeutics, Inc. | $CCCC | Siegel Jolie | Chief Legal Officer | A | Stock Option (Right to Buy) | 90000 | $0.00 | 90,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 13, 2024 | C4 Therapeutics, Inc. | $CCCC | Siegel Jolie | Chief Legal Officer | F | Common Stock | 1735 | $6.53 | 24,951.0000 | 0 | 6.50% | 0.00% |
| Feb. 14, 2024 | C4 Therapeutics, Inc. | $CCCC | Siegel Jolie | Chief Legal Officer | A | Common Stock | 27300 | $0.00 | 52,251.0000 | 0 | 109.41% | 0.00% |
| Feb. 14, 2024 | C4 Therapeutics, Inc. | $CCCC | Siegel Jolie | Chief Legal Officer | A | Stock Option (Right to Buy) | 122800 | $0.00 | 122,800.0000 | 0 | 9999.99% | 0.00% |